Move to topTop
March 29, 2022
TOKYO, JAPAN - March 29, 2022 - Terumo Corporation (TSE: 4543) today announced that the company commits to achieve carbon neutrality* by 2040 to further mitigate climate change risks. To achieve this goal, Terumo has revised its greenhouse gas (GHG) emission reduction target (Scope 1 and 2) as well as setting a new target to promote the use of renewable energy such as solar power, in addition to conventional energy saving activities. Furthermore, Terumo also advocates GHG emission reductions throughout the value chain such as reducing waste, making effective use of natural resources, developing environmentally friendly products, and advancing joint delivery with other companies.

Based on this revision of the GHG emission reduction target, Terumo has applied to the Science Based Targets initiative (SBTi) for an updated certificate to the "1.5°C target" which is in line with a level to limit the temperature rise to 1.5°C above pre-industrial levels. Terumo received an approval by SBTi in March 2020 for the previous target that commits to pursue global warming prevention efforts of well-below 2°C above pre-industrial levels.

Terumo has also publicly declared its support for the Task Force on Climate-related Financial Disclosures (TCFD) and its recommendations, which was established by the Financial Stability Board (FSB).

Under the Group's corporate mission of "Contributing to Society through Healthcare", Terumo has strived to advance healthcare and enhance patients' quality of life. In addition, Terumo has established the Terumo Group Sustainability Policy in 2021 to solidly realize its Group mission. To reduce the environmental impact of Terumo's business is a part of the sustainability priorities listed in the Policy. By ambitiously committing to achieve carbon neutrality, Terumo Group will work towards shrinking the global issue of climate change.


 

  • * Carbon neutrality means having a balance between emitting carbon and absorbing carbon.




Terumo Group's target of GHG emission reduction

Scope 1 and 2
  • ・Reduce absolute GHG emissions 50% by 2030 from a 2018 base year
  • ・Increase a ratio of renewable electricity use up to 50% by 2030
  • ・Achieve carbon neutrality by 2040

Scope 3
・Reduce GHG emissions 60% per unit of revenue by 2030 from a 2018 base year
 
(Scope definition)
Scope 1: Direct GHG emissions by the company (e.g. fuel combustion)
Scope 2: Electricity indirect GHG emissions (e.g. GHG emissions from electric companies)
Scope 3: Other indirect GHG emissions (e.g. production of purchased materials, transportation, and waste disposal)


 

  • 20220329-1

     

  •  

Reference: Reducing Environmental Footprint

About SBTi

The Science Based Targets initiative (SBTi) is a partnership between CDP, the United Nations Global Compact, World Resources Institute (WRI) and the World Wide Fund for Nature (WWF). SBTi promotes companies to establish science-based GHG reduction targets to keep the global average temperature rise to 1.5°C above pre-industrial levels.

 

About TCFD

TCFD is the Task Force on Climate Related Financial Information Disclosure, which was established by the Financial Stability Board (FSB) at the request of the G20 to consider how to deal with climate-related information disclosure and financial institutions. In June 2017, TCFD had encouraged companies and organizations to voluntarily capture and disclose information on the financial implications of climate-related risks and opportunities.

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

 

Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.